CARTITUDE-1 Primary Findings Discussion
Panelists discuss how the 5-year data from CARTITUDE-1 demonstrate that a substantial subset of patients achieved long-term remission, suggesting a potential shift toward curative therapy.
EP: 1.Treatment Approaches in Multiple Myeloma
EP: 2.FDA Approvals for Multiple Myeloma
EP: 3.CARTITUDE-1 Baseline Demographics
EP: 4.An Overview of CARTITUDE-1
EP: 5.CARTITUDE-1 Patients
EP: 6.CARTITUDE-1 Efficacy Findings
EP: 7.CARTITUDE-1 Safety Overview
EP: 8.CARTITUDE-1 Primary Findings Discussion
Five-year follow-up data from CARTITUDE-1 revealed that approximately 30% of patients remained progression free, a historic milestone in relapsed/refractory myeloma. This is the first study to report such long-term results in this setting.
Patients who remained progression free were found to have characteristics like lower baseline tumor burden and more favorable immune profiles, such as higher T-cell fitness and greater expansion of chimeric antigen receptor (CAR) T cells.
Interestingly, high-risk features such as poor cytogenetics and extramedullary disease were evenly distributed among both long-term responders and early relapsers, challenging assumptions about who may benefit most from CAR T-cell therapy.
